Agati Salvatore, Mignosa Carmelo, Gitto Placido, Trimarchi Eugenio Santo, Ciccarello Giuseppe, Salvo Dario, Trimarchi Giuseppe
Pediatric Cardiac Surgery Unit, San Vincenzo Hospital, Taormina, Messina, Italy.
J Thorac Cardiovasc Surg. 2006 Jun;131(6):1306-9. doi: 10.1016/j.jtcvs.2006.02.013.
The purposes of this study were to evaluate the clinical safety and efficacy of 10F, 15F, and 19F Blake drains (Ethicon, Sommerville, NJ) in a pediatric population after cardiac surgery and to compare their clinical effect with that of conventional chest drains.
From January 2002 through December 2004, a prospective randomized trial was conducted on 189 patients who underwent surgical intervention for congenital heart disease at our institution. Statistical analyses were conducted to test the null hypothesis that there was no difference in the incidence of pericardial or pleural effusion requiring drainage. Secondary end points included total volume of drainage, drain size, and time to drain removal.
Ninety-eight patients (group A) received Blake drains, and 91 patients (group B) received conventional chest drains. There were no statistically significant difference in age, weight at the time of surgical intervention, open- and closed-heart procedures, and number of drains applied. Statistically significant differences were detected in the frequency of pericardial effusion (group A: 1.1% vs group B: 4.8%, P < .01), pleural effusion (group A: 1.1% vs group B: 5.3%, P < .01), size of the drain (group A: 12.37 French +/- 1.72 French vs group B: 16.81 French +/- 0.70 French, P < .001), and time to removal (group A: 43.75 +/- 20.76 hours vs group B: 55.62 +/- 26.48 hours, P < .001).
Blake drains are safer and more efficient than conventional chest tubes in pediatric populations after cardiac surgery. In comparison with conventional chest tubes, they showed fewer occurrences of effusions and the same amount of fluid drained but smaller size and earlier removal.
本研究旨在评估10F、15F和19F布雷克引流管(美国新泽西州萨默维尔市的Ethicon公司生产)在小儿心脏手术后的临床安全性和有效性,并将其临床效果与传统胸管进行比较。
从2002年1月至2004年12月,对在我院接受先天性心脏病手术干预的189例患者进行了一项前瞻性随机试验。进行统计分析以检验零假设,即需要引流的心包积液或胸腔积液的发生率没有差异。次要终点包括引流总量、引流管尺寸和拔管时间。
98例患者(A组)接受了布雷克引流管,91例患者(B组)接受了传统胸管。在手术干预时的年龄、体重、心脏直视和非心脏直视手术以及应用的引流管数量方面,两组之间没有统计学上的显著差异。在心包积液的发生率(A组:1.1% vs B组:4.8%,P <.01)、胸腔积液的发生率(A组:1.1% vs B组:5.3%,P <.01)、引流管尺寸(A组:12.37法式±1.72法式 vs B组:16.81法式±0.70法式,P <.001)和拔管时间(A组:43.75±20.76小时 vs B组:55.62±26.48小时,P <.001)方面检测到统计学上的显著差异。
在小儿心脏手术后,布雷克引流管比传统胸管更安全、更有效。与传统胸管相比,它们积液发生较少,引流量相同,但尺寸更小且拔管更早。